Pulse lineResearch With Heart Logo

ARIC Publications

Filters: Keyword is Biomarkers  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Agarwal SK, Chambless LE, Ballantyne CM, et al. "Prediction of incident heart failure in general practice: the Atherosclerosis Risk in Communities (ARIC) Study." Circ Heart Fail. 2012;5(4):422-9.
Agarwal SK, Avery CL, Ballantyne CM, et al. "Sources of variability in measurements of cardiac troponin T in a community-based sample: the atherosclerosis risk in communities study." Clin Chem. 2011;57(6):891-7.
Agarwala A, Pokharel Y, Saeed A, et al. "The association of lipoprotein(a) with incident heart failure hospitalization: Atherosclerosis Risk in Communities study." Atherosclerosis. 2017;262:131-137.
Agarwala A, Virani S, Couper DJ, et al. "Biomarkers and degree of atherosclerosis are independently associated with incident atherosclerotic cardiovascular disease in a primary prevention cohort: The ARIC study." Atherosclerosis. 2016;253:156-163.
Almuwaqqat Z, O'Neal WT, Norby FL, et al. "Joint Associations of Obesity and NT-proBNP With the Incidence of Atrial Fibrillation in the ARIC Study." J Am Heart Assoc. 2019;8(19):e013294.
Alonso A, Tang W, Agarwal SK, Soliman EZ, Chamberlain AM. "Hemostatic markers are associated with the risk and prognosis of atrial fibrillation: the ARIC study." Int J Cardiol. 2012;155(2):217-22.
Alonso A, Rooney MR, Chen LYee, et al. "Circulating electrolytes and the prevalence of atrial fibrillation and supraventricular ectopy: The Atherosclerosis Risk in Communities (ARIC) study." Nutr Metab Cardiovasc Dis. 2020;30(7):1121-1129.
Alonso A, Misialek JR, Amiin MA, et al. "Circulating levels of liver enzymes and incidence of atrial fibrillation: the Atherosclerosis Risk in Communities cohort." Heart. 2014;100(19):1511-6.
Alonso A, Misialek JR, Eckfeldt JH, et al. "Circulating fibroblast growth factor-23 and the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities study." J Am Heart Assoc. 2014;3(5):e001082.
Alonso A, Yu B, Sun YV, et al. "Serum Metabolomics and Incidence of Atrial Fibrillation (from the Atherosclerosis Risk in Communities Study)." Am J Cardiol. 2019;123(12):1955-1961.
Appiah D, Schreiner PJ, Maclehose RF. "Association of Plasma γ' Fibrinogen With Incident Cardiovascular Disease: The Atherosclerosis Risk in Communities (ARIC) Study." Arterioscler Thromb Vasc Biol. 2015;35(12):2700-6.
Aronis KN, Zhao D, Hoogeveen RC, et al. "Associations of Lipoprotein(a) Levels With Incident Atrial Fibrillation and Ischemic Stroke: The ARIC (Atherosclerosis Risk in Communities) Study." J Am Heart Assoc. 2017;6(12).
Astor BC, Shafi T, Hoogeveen RC, Matsushita K, Ballantyne CM, Inker LA. "Novel markers of kidney function as predictors of ESRD, cardiovascular disease, and mortality in the general population." Am J Kidney Dis. 2012;59(5):653-62.
Astor BC, Köttgen A, Hwang S-J, Bhavsar N, Fox CS. "Trefoil factor 3 predicts incident chronic kidney disease: a case-control study nested within the Atherosclerosis Risk in Communities (ARIC) study." Am J Nephrol. 2011;34(4):291-7.
Avery CL, Kucharska-Newton AMaria, Monda KL, et al. "Impact of long-term measures of glucose and blood pressure on the retinal microvasculature." Atherosclerosis. 2012;225(2):412-7.
B
Ballantyne CM, Hoogeveen RC, Bang H, et al. "Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study." Arch Intern Med. 2005;165(21):2479-84.
Ballantyne CM, Hoogeveen RC, Bang H, Coresh JJ, Folsom AR, Heiss G. "Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study." Circulation. 2004;109(7):837-42.
Ballew SH, Chen Y, Daya NR, et al. "Frailty, Kidney Function, and Polypharmacy: The Atherosclerosis Risk in Communities (ARIC) Study." Am J Kidney Dis. 2017;69(2):228-236.
Barros SP, Suruki R, Loewy ZG, Beck JD. "A cohort study of the impact of tooth loss and periodontal disease on respiratory events among COPD subjects: modulatory role of systemic biomarkers of inflammation." PLoS One. 2013;8(8):e68592.
Bash LD, Erlinger TP, Coresh JJ, Marsh-Manzi J, Folsom AR. "Inflammation, hemostasis, and the risk of kidney function decline in the Atherosclerosis Risk in Communities (ARIC) Study." Am J Kidney Dis. 2009;53(4):596-605.
Bash LD, Coresh JJ, Köttgen A, Parekh RS, Fulop T, Wang Y. "Defining incident chronic kidney disease in the research setting: The ARIC Study." Am J Epidemiol. 2009;170(4):414-24.
Begum F, Ruczinski I, Li S, et al. "Identifying a Deletion Affecting Total Lung Capacity Among Subjects in the COPDGene Study Cohort." Genet Epidemiol. 2016;40(1):81-8.
Bhavsar NA, Köttgen A, Coresh JJ. "Neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule 1 (KIM-1) as predictors of incident CKD stage 3: the Atherosclerosis Risk in Communities (ARIC) Study." Am J Kidney Dis. 2012;60(2):233-40.
Breslow NE, Lumley T, Ballantyne CM, Chambless LE. "Using the whole cohort in the analysis of case-cohort data." Am J Epidemiol. 2009;169(11):1398-405.
C
Carnethon MR, Palaniappan LP, Burchfiel CM, Brancati FL. "Serum insulin, obesity, and the incidence of type 2 diabetes in black and white adults: the atherosclerosis risk in communities study: 1987-1998." Diabetes Care. 2002;25(8):1358-64.
Catellier DJ, Aleksic N, Folsom AR. "Atherosclerosis Risk in Communities (ARIC) Carotid MRI flow cytometry study of monocyte and platelet markers: intraindividual variability and reliability." Clin Chem. 2008;54(8):1363-71.
Caughey MC, Derebail VK, Key NS, Reiner AP, Gottesman RF, Kshirsagar AV. "Thirty-year risk of ischemic stroke in individuals with sickle cell trait and modification by chronic kidney disease: The atherosclerosis risk in communities (ARIC) study." Am J Hematol. 2019;94(12):1306-1313.
Chambless LE, Folsom AR, Sharrett ARichey, Sorlie P, Couper DJ, Szklo M. "Coronary heart disease risk prediction in the Atherosclerosis Risk in Communities (ARIC) study." J Clin Epidemiol. 2003;56(9):880-90.
Chambless LE, Heiss G, Shahar E, Earp M J. "Prediction of ischemic stroke risk in the Atherosclerosis Risk in Communities Study." Am J Epidemiol. 2004;160(3):259-69.
Chatterjee R, Brancati FL, Shafi T, et al. "Non-traditional risk factors are important contributors to the racial disparity in diabetes risk: the atherosclerosis risk in communities study." J Gen Intern Med. 2014;29(2):290-7.
Chatterjee R, Davenport CA, Raffield LM, et al. "KCNJ11 variants and their effect on the association between serum potassium and diabetes risk in the Atherosclerosis Risk in Communities (ARIC) Study and Jackson Heart Study (JHS) cohorts." PLoS One. 2018;13(8):e0203213.
Chen H, Mosley TH, Alonso A, Huang X. "Plasma urate and Parkinson's disease in the Atherosclerosis Risk in Communities (ARIC) study." Am J Epidemiol. 2009;169(9):1064-9.
Cushman M, O'Meara ES, Heckbert SR, Zakai NA, Rosamond WD. "Body size measures, hemostatic and inflammatory markers and risk of venous thrombosis: The Longitudinal Investigation of Thromboembolism Etiology." Thromb Res. 2016;144:127-32.
D
Dadu RT, Fornage M, Virani SS, et al. "Cardiovascular biomarkers and subclinical brain disease in the atherosclerosis risk in communities study." Stroke. 2013;44(7):1803-8.
Dadu RT, Dodge R, Nambi V, et al. "Ceruloplasmin and heart failure in the Atherosclerosis Risk in Communities study." Circ Heart Fail. 2013;6(5):936-43.
de Larriva APArenas, Norby FL, Chen LYee, et al. "Circulating ceruloplasmin, ceruloplasmin-associated genes, and the incidence of atrial fibrillation in the atherosclerosis risk in communities study." Int J Cardiol. 2017;241:223-228.
de Larriva APArenas, Alonso A, Norby FL, Roetker NS. "Circulating ceruloplasmin, ceruloplasmin-associated genes and the incidence of venous thromboembolism in the Atherosclerosis Risk in Communities study." J Thromb Haemost. 2019;17(5):818-826.
DeBoer MD, Filipp SL. "Associations of a metabolic syndrome severity score with coronary heart disease and diabetes in fasting vs. non-fasting individuals." Nutr Metab Cardiovasc Dis. 2020;30(1):92-98.
Dehghan A, Dupuis J, Barbalic M, et al. "Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels." Circulation. 2011;123(7):731-8.
Dhana K, Braun KVE, Nano J, et al. "An Epigenome-Wide Association Study of Obesity-Related Traits." Am J Epidemiol. 2018;187(8):1662-1669.
Ding N, Kwak L, Ballew SH, et al. "Traditional and nontraditional glycemic markers and risk of peripheral artery disease: The Atherosclerosis Risk in Communities (ARIC) study." Atherosclerosis. 2018;274:86-93.
Ding N, Yang C, Ballew SH, et al. "Fibrosis and Inflammatory Markers and Long-Term Risk of Peripheral Artery Disease: The ARIC Study." Arterioscler Thromb Vasc Biol. 2020;40(9):2322-2331.
Duncan BB, Schmidt MI, Chambless LE, Folsom AR, Carpenter M. "Fibrinogen, other putative markers of inflammation, and weight gain in middle-aged adults--the ARIC study. Atherosclerosis Risk in Communities." Obes Res. 2000;8(4):279-86.
Duncan BB, Schmidt M I, Chambless LE, Folsom AR. "Inflammation markers predict increased weight gain in smoking quitters." Obes Res. 2003;11(11):1339-44.
E
Ebong IA, Wilson MD, Bertoni AG, et al. "High-sensitivity cardiac troponin T and the risk of heart failure in postmenopausal women of the ARIC Study." Menopause. 2021;28(3):284-291.
Ellis J, Lange EM, Li J, et al. "Large multiethnic Candidate Gene Study for C-reactive protein levels: identification of a novel association at CD36 in African Americans." Hum Genet. 2014;133(8):985-95.
Kaptoge S, Di Angelantonio E, Pennells L, et al. "C-reactive protein, fibrinogen, and cardiovascular disease prediction." N Engl J Med. 2012;367(14):1310-20.
F
Fashanu OE, Norby FL, Aguilar D, et al. "Galectin-3 and incidence of atrial fibrillation: The Atherosclerosis Risk in Communities (ARIC) study." Am Heart J. 2017;192:19-25.
Florido R, Lee AK, McEvoy JW, et al. "Cancer Survivorship and Subclinical Myocardial Damage." Am J Epidemiol. 2019;188(12):2188-2195.
Florido R, Kwak L, Lazo M, et al. "Six-Year Changes in Physical Activity and the Risk of Incident Heart Failure: ARIC Study." Circulation. 2018;137(20):2142-2151.
Florido R, Ndumele CE, Kwak L, et al. "Physical Activity, Obesity, and Subclinical Myocardial Damage." JACC Heart Fail. 2017;5(5):377-384.
Folsom AR, Lutsey PL, Heckbert SR, et al. "Longitudinal increases in blood biomarkers of inflammation or cardiovascular disease and the incidence of venous thromboembolism." J Thromb Haemost. 2018;16(10):1964-1972.
Folsom AR, Chambless LE, Ballantyne CM, et al. "An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study." Arch Intern Med. 2006;166(13):1368-73.
Folsom AR, Rosamond WD, Shahar E, et al. "Prospective study of markers of hemostatic function with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators." Circulation. 1999;100(7):736-42.
Folsom AR, Aleksic N, Catellier D, Juneja HS. "C-reactive protein and incident coronary heart disease in the Atherosclerosis Risk In Communities (ARIC) study." Am Heart J. 2002;144(2):233-8.
Folsom AR, Nambi V, Pankow JS, Tang W, Farbakhsh K, Yamagishi K. "Effect of 9p21 genetic variation on coronary heart disease is not modified by other risk markers. The Atherosclerosis Risk in Communities (ARIC) Study." Atherosclerosis. 2012;224(2):435-9.
Folsom AR, Lutsey PL, Nambi V, Defilippi CR, Heckbert SR, Cushman M. "Troponin T, NT-proBNP, and venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE)." Vasc Med. 2014;19(1):33-41.
Folsom AR, Cushman M, Heckbert SR, Rosamond WD. "Prospective study of fibrinolytic markers and venous thromboembolism." J Clin Epidemiol. 2003;56(6):598-603.
Folsom AR, Gottesman RF, Appiah D, Shahar E. "Plasma d-Dimer and Incident Ischemic Stroke and Coronary Heart Disease: The Atherosclerosis Risk in Communities Study." Stroke. 2016;47(1):18-23.
Folsom AR, Nambi V, Bell EJ, et al. "Troponin T, N-terminal pro-B-type natriuretic peptide, and incidence of stroke: the atherosclerosis risk in communities study." Stroke. 2013;44(4):961-7.
Folsom AR, Desvarieux M, Nieto JF, Boland LL, Ballantyne CM. "B vitamin status and inflammatory markers." Atherosclerosis. 2003;169(1):169-74.
Folsom AR, Lutsey PL, Astor BC. "C-reactive protein and venous thromboembolism. A prospective investigation in the ARIC cohort." Thromb Haemost. 2009;102(4):615-9.
Folsom AR, Yao L, Alonso A, et al. "Circulating Biomarkers and Abdominal Aortic Aneurysm Incidence: The Atherosclerosis Risk in Communities (ARIC) Study." Circulation. 2015;132(7):578-85.
Folsom AR, Aleksic N, Park E, Salomaa V, Juneja H. "Prospective study of fibrinolytic factors and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study." Arterioscler Thromb Vasc Biol. 2001;21(4):611-7.
Folsom AR, Lutsey PL, Heckbert SR. "Serum albumin and risk of venous thromboembolism." Thromb Haemost. 2010;104(1):100-4.
Foster MC, Coresh JJ, Bonventre JV, et al. "Urinary Biomarkers and Risk of ESRD in the Atherosclerosis Risk in Communities Study." Clin J Am Soc Nephrol. 2015;10(11):1956-63.
Fretz A, McEvoy JW, Rebholz CM, et al. "Relation of Lifestyle Factors and Life's Simple 7 Score to Temporal Reduction in Troponin Levels Measured by a High-Sensitivity Assay (from the Atherosclerosis Risk in Communities Study)." Am J Cardiol. 2018;121(4):430-436.
Fretz A, Schneider ALC, McEvoy JW, Hoogeveen RC, Ballantyne CM, Coresh JJ. "The Association of Socioeconomic Status With Subclinical Myocardial Damage, Incident Cardiovascular Events, and Mortality in the ARIC Study." Am J Epidemiol. 2016;183(5):452-61.
G
Garg PK, Norby FL, Polfus LM, et al. "Lipoprotein-associated phospholipase A and risk of incident peripheral arterial disease: Findings from The Atherosclerosis Risk in Communities study (ARIC)." Atherosclerosis. 2018;268:12-18.
Gaubatz JW, Ballantyne CM, Wasserman BA, He M, Chambless LE, Boerwinkle E. "Association of circulating matrix metalloproteinases with carotid artery characteristics: the Atherosclerosis Risk in Communities Carotid MRI Study." Arterioscler Thromb Vasc Biol. 2010;30(5):1034-42.
Georgakis MK, Malik R, Björkbacka H, et al. "Circulating Monocyte Chemoattractant Protein-1 and Risk of Stroke: Meta-Analysis of Population-Based Studies Involving 17 180 Individuals." Circ Res. 2019;125(8):773-782.
Ghaddar HB, Cortes J, Salomaa V, et al. "Correlation of specific platelet activation markers with carotid arterial wall thickness." Thromb Haemost. 1995;74(3):943-8.
M Gore O, Seliger SL, Defilippi CR, et al. "Age- and sex-dependent upper reference limits for the high-sensitivity cardiac troponin T assay." J Am Coll Cardiol. 2014;63(14):1441-8.
Gori M, Gupta DK, Claggett B, et al. "Natriuretic Peptide and High-Sensitivity Troponin for Cardiovascular Risk Prediction in Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study." Diabetes Care. 2016;39(5):677-85.
Gottesman RF, Cummiskey C, Chambless L, Wu KK, Aleksic N, Folsom AR. "Hemostatic factors and subclinical brain infarction in a community-based sample: the ARIC study." Cerebrovasc Dis. 2009;28(6):589-94.
Grams ME, Waikar SS, MacMahon B, Whelton S, Ballew SH. "Performance and limitations of administrative data in the identification of AKI." Clin J Am Soc Nephrol. 2014;9(4):682-9.
Gurka MJ, Guo Y, Filipp SL. "Metabolic syndrome severity is significantly associated with future coronary heart disease in Type 2 diabetes." Cardiovasc Diabetol. 2018;17(1):17.

Pages